Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1806310 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $5.61Day +2.75%Mkt cap $1.6B1Y +114.1%Off 52W high −23.2%Vol (1Y) 90.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest15.8% of sh out |
| Days to cover13.3d |
| 13F net flow (QoQ)+1.09% |
| Top-10 13F concentration64.5% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$7.5M |
| Earnings (TTM)-$129.9M |
| ROE−68.5% |
| Net margin−1115.3% |
| Debt / equity0.20× |
| Sales growth 3Y57.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+2.0% |
| 1Y+114.1% |
| 3Y+733.3% |
| 5Y−67.6% |
| Since incept. (ann.)−26.2% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)90.4% |
| Ann. volatility (3Y)149.9% |
| Sharpe (1Y)1.24 |
| Sharpe (3Y)0.99 |
| Max drawdown (1Y)−31.1% |
| Max drawdown (3Y)−72.9% |
| Beta (3Y vs SPY)0.96 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 23.6M | $105M | 8.20% | +0.0% |
| GOLDMAN SACHS GROUP INC | 22.4M | $100M | 7.78% | +63.4% |
| Avoro Capital Advisors LLC | 21.7M | $97M | 7.55% | +0.0% |
| BlackRock, Inc. | 18.4M | $82M | 6.39% | −1.5% |
| Vestal Point Capital, LP | 18.0M | $80M | 6.26% | +30.9% |
| MORGAN STANLEY | 18.0M | $80M | 6.25% | −0.6% |
| FMR LLC | 14.3M | $64M | 4.98% | +5.9% |
| RTW INVESTMENTS, LP | 13.7M | $61M | 4.76% | −16.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.12 | — | $0 | −100.0% |
| 2025-12-31 | 2026-03-19 | — | — | $5.5M | +171.3% |
| 2025-09-30 | 2025-11-04 | −$0.09 | — | $0 | −100.0% |
| 2025-06-30 | 2025-08-12 | −$0.09 | — | $2.0M | +78.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 90d) — not company-confirmed.
